Nifty 200

Zydus Lifesciences has informed that it enclosed a copy of press release dated October 21, 2026, titled ‘Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity’. The contents of the press release give full details.

The above information is a part of company’s filings submitted to BSE.

LTM has informed that it enclosed a copy of the Press Release titled ‘LTM Launches BlueVerse™ ValueMesh™ to Help Enterprises Scale AI Across Oracle Transformations’. 

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, State Bank of India has informed that the Bank has experienced an incident involving the loss of certain data. On 16 October 2026, the Bank received communications from its Threat Intelligence Service Provider, the Defence Cyber Agency, and CERT-In regarding an alert concerning the suspected exposure of the Bank’s customer data on the dark web. During the preliminary analysis of approximately 375,000 records available on the dark web, 3,897 customer records containing Personally Identifiable Information (PII) were identified. The exposed information reportedly included customers’ registered mobile numbers, dates of birth, names, gender, email addresses, residential addresses, branch and CIF identifiers, lead IDs, and metadata associated with loan/lead records and other related files. A detailed investigation was required to establish the authenticity and completeness of the exposed data, determine the potential source and extent of the exposure, and assess the associated risks to customers and the Bank. The Bank promptly activated its cyber incident response and containment protocols. Additionally, an independent CERT-In-empanelled cybersecurity agency was engaged to conduct a comprehensive assessment and investigate the nature and extent of the alleged compromise. The company has informed that this does not have any material impact on Bank’s Core business operations, financial performance or business continuity. The Bank’s core business functions continue to operate normally without disruptions. A detailed assessment is currently underway and appropriate remedial and preventive measures are being implemented as required. The company has reassured that the Bank continues to monitor the situation closely and take all appropriate measures in accordance with applicable regulatory requirements.

The above information is a part of company’s filings submitted to BSE.

PB Fintech has informed that it enclosed disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddy’s Laboratories has informed that it enclosed a Press Release ‘Dr. Reddy’s Receives DCGI Approval for Zytorvi® (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India’.

The above information is a part of company’s filings submitted to BSE.